Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, generic drug giant Teva Pharmaceutical Industries (TEVA) has earned a coveted five-star ranking.
With that in mind, let's take a closer look at Teva and see what CAPS investors are saying about the stock right now.
Teva facts
|
Headquarters (founded) |
Petach Tikva, Israel (1901) |
|
Market Cap |
$32.6 billion |
|
Industry |
Pharmaceuticals |
|
Trailing-12-Month Revenue |
$20.3 billion |
|
Management |
CEO Dr. Jeremy Levin (since 2010) |
|
Return on Equity (average, past 3 years) |
12.4% |
|
Cash/Debt |
$2.9 billion / $14.7 billion |
|
Dividend Yield |
2.8% |
|
Competitors |
Actavis |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 98% of the 1,769 members who have rated Teva believe the stock will outperform the S&P 500 going forward.
Just last week, one of those Fools, MMcCabeNMC, succinctly summed up the Teva bull case for our community:
Teva is a huge generic drug maker, with some outreach into the primary drug market. The company's balance sheet is strong, and the stock pays a reasonable dividend. With governments emphasizing cost controls for medical expense, Teva has a guaranteed market.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
